immune system

IRP’s Michael Lenardo Elected to National Academy of Sciences

NIH Researcher Recognized for Enhancing the Molecular Understanding of Immune Responses

Dr. Michael Lenardo

The National Academy of Sciences (NAS), established in 1863, is comprised of the United States’ most distinguished scientific scholars, including nearly 500 Nobel Prize winners. Members of the NAS are elected by their peers and entrusted with the responsibility of providing independent, objective advice on national matters related to science and technology in an effort to advance innovations in the United States.

IRP senior investigator Michael Lenardo, M.D., is one of four IRP researchers elected to the NAS over the past two years. At the NIH, Dr. Lenardo serves as Chief of the Molecular Development of the Immune System Section at the NIH’s National Institute of Allergy and Infectious Diseases (NIAID), where he studies how the cells in the immune system mount protective responses to various pathogens, including viruses and bacteria. A major focus of Dr. Lenardo’s work is the investigation of genetic abnormalities in the immune system, which have the potential to cause life-threatening diseases.

Three-Armed Antibody Could Offer Defense Against AIDS

Four Questions with Dr. John Mascola

HIV-infected T cell

The disease known as human immunodeficiency virus, or HIV, attacks and destroys cells vital to the immune system. This leaves the millions of people living with HIV less able to fight other infections and can lead to an extremely severe form of immune system deficiency called acquired immunodeficiency syndrome (AIDS), which was responsible for nearly 770,000 deaths in 2018 alone. As of 2019, there are approximately 37.9 million people around the world living with HIV/AIDS.

Although HIV/AIDS has been recognized as a serious public health crisis, finding effective treatments, or a vaccine to prevent infection in the first place, is not a simple task. The HIV virus has many different types and strains — similar to the flu — which makes developing vaccines and treatments extremely challenging, as the virus is constantly changing. At the NIH, there are a number of ongoing collaborative research projects aimed at providing new options for those diagnosed with HIV/AIDS and those at risk for contracting the virus in the future.

Antibiotics Could Assist Liver Cancer Care

Four Questions with Dr. Tim Greten

medications

There are over 100 different types of cancer, with liver, breast, and colon cancers among the most common. At the NIH, researchers across the organization have long been committed to furthering cancer research in an effort to increase the number of cancer survivors. They consistently push the boundaries of this field each day in the hopes that their work could lead to better diagnoses, better treatment, and better outcomes for cancer patients.

A 2018 study by IRP senior investigator Tim Greten, M.D., and his IRP colleagues did just that and more. Their research pushed the norms of cancer research by studying how a treatment as simple as antibiotics affects cancerous liver tumors. By utilizing antibiotics to wipe out the collection of microorganisms living in the digestive tracts of mice — known as the gut microbiome — the team identified a link between the gut microbiome and the behavior of the liver’s immune cells, which play a role in defending the organ against cancer. The IRP team ultimately showed that antibiotic treatment reduced the development of liver tumors in these ‘germ-free’ mice, and it also reduced the likelihood that tumors in other areas of the body would metastasize — or spread — to the animals’ livers, a finding that could one day prove beneficial to future cancer patients.

NIH Research Festival Hosts Postdoc Poster-Palooza

Annual Event Highlights Contributions of IRP Postdoctoral Fellows

Dr. Subhash Verma

At lunchtime last Wednesday, the NIH Clinical Center’s FAES Terrace echoed with the joyful sounds of scientists nourishing their bodies and their brains. While those stopping by the annual NIH Research Festival poster session could be forgiven for making a beeline straight for the food — including the submissions to this year’s Scientific Directors’ baking competition — once their plates were full, they took advantage of the opportunity to satiate their scientific curiosity as well by checking out the dozens of posters on display.

Rare Disease Research Reveals Why Immune Cells Go Wild

Discovery Could Improve Therapy for Multiple Autoimmune Diseases

neutrophil extracellular traps (NETs)

Hiding among YouTube’s vast collection of cooking demos and funny cat videos are clips of patients and their advocates designed to raise awareness of specific diseases. It was just such a video that led IRP Senior Investigator Peter Grayson, M.D., M.Sc., to begin studying an extremely rare illness called deficiency of adenosine deaminase 2, or DADA2 for short. The recently published findings of that research could help improve treatment not just for patients with DADA2 but also many more individuals with similar ailments.

Poster Day Showcases Summer Student Science

Annual Event Shares Research by IRP’s Summer Interns

IRP summer intern Enat Ayele

NIH’s Natcher Conference Center was packed once again last Thursday for the annual Summer Poster Day. This year, more than 1,200 college and high school students spent their summer performing research in an IRP lab through the NIH’s Summer Internship Program. 

I navigated through the more than 900 posters presented this year to get a taste of the impressive work done by these young men and women in less than three months. If they can make these kinds of discoveries in just one summer, imagine what they might one day accomplish as full-time scientists and clinicians!

HIV Research Yields an Unexpected Discovery

A Conversation with Dr. Paolo Lusso

Dr. Paolo Lusso

First discovered in 1981, human immunodeficiency virus, or HIV, caused one of the most deadly and persistent epidemics in history. HIV destroys CD4+ T cells, a type of white blood cell essential for fighting infection. In doing so, HIV destroys the body’s ability to fight off disease, which often leads to life-threatening consequences. 

Today, medications have allowed people living with HIV to lead healthier lives. However, HIV still remains a major public health concern and continues to be studied by researchers within the IRP and beyond.

IRP research has produced findings essential to the development of current HIV treatments and tools for diagnosis. However, there is still a lot left to learn. One recent IRP contribution to HIV research was a 2017 study led by IRP senior investigator Paolo Lusso, M.D., Ph.D., which suggests that treatments targeting a protein called integrin α4β7 could potentially become an addition to current treatment options for those with HIV, or provide new measures to prevent infection.

Non-Toxic Drug Could Increase Availability of Organ Transplants

Treatment Regimen Allows Genetically Mismatched Skin Grafts in Mice

surgeons performing an organ transplant

Thousands of patients who need an organ transplant die each year before a donor can be found. A new IRP study has identified a safer way to prevent a transplant recipient’s body from attacking a genetically dissimilar donor organ, which could dramatically expand the pool of potential organ donors.

Tracing the Pathway From Skin Irritation to Itching

Disrupting Itch-Related Process Could Relieve Relentless Itching

person scratching their skin

For most people, the arrival of spring time means more time spent outdoors — and greater exposure to nuisances like biting insects and poison ivy that make us itch. New IRP research has revealed a detailed picture of how a particular type of cell causes itching, findings that may ultimately help researchers develop treatments for disorders that cause severe and long-lasting itch.

Overlooked Immune Cells Trigger Preterm Labor

New Insights Could Help Reduce Premature Births

mother and newborn baby

Any baby born less than 37 weeks after conception is considered premature, but not all premature births have the same root cause. In a new study, IRP researchers have detailed how a particular component of the immune system can trigger premature labor, which could help doctors prevent more preterm births.